The primary adverse events observed in patients who received CD19/CD22 BS Loop CAR therapy included Grade I CRS (20%, 1/5), with no notable increases in serum cytokine levels and no evidence of neurotoxicity, even among patients with a substantial disease burden. This evidence concerns the gene CD22 and congenital rubella syndrome.